Alnylam Pharmaceuticals, Inc.
ALNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178670
In the last 90 days, Alnylam Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 797 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $21.4B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $398.9K in total
- 1
- 13F holdersQ2 2026, +6 vs. previous quarter
- 797
- 13F valueReported value at the end of Q2 2026
- $40.1B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $3.71B
- +65.2% year over year
- Net income, FY2025
- $313.7M
- No comparable prior period
- Free cash flow, FY2025
- $465.4M
- No comparable prior period
- Revenue, Q3 FY2026
- $1.46B
- +16.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.47M
- Shares sold short
- Change
- −1.10M
- −16.8% vs. previous
- Days to cover
- 1.91
- At average daily volume
Superinvestors holding ALNY, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ALNY at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Alnylam Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 2026 (view filing)4:12 PM ET | Oct 2 | 4 days | Supran BryanEVP, CLO and Secretary | SSale | −1.76K | $226.88 | −$398.9K | −12.1%12.8K after | |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Pyott David E IDirector | SSale | −3.83K | $299.18 | −$1.15M | −70.8%1.58K after | 5 lots10b5-1 |
| Apr 7, 2026 (view filing) | Apr 2-6 | 5 daysLate | McLaughlin MelissaChief Human Resources Officer | SSale | −3.91K | $325.92 | −$1.27M | −29.3%9.44K after | 14 lots10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4-5 | 2 days | Garg PushkalEVP Chief R&D | SSale | −4.71K | $323.53 | −$1.52M | −20.1%18.7K after | 12 lots10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Greenstreet YvonneChief Executive Officer | SSale | −2.93K | $323.08 | −$947.6K | −3.0%95.7K after | 8 lots |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Poulton Jeffrey V.EVP, Chief Financial Officer | SSale | −2.47K | $323.08 | −$797.4K | −3.8%61.8K after | 8 lots |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Tanguler TolgaEVP, Chief Commercial Officer | SSale | −2.31K | $323.08 | −$746.0K | −6.3%34.3K after | 8 lots |
| Mar 6, 2026 (view filing) | Mar 4-5 | 2 days | Fitzgerald Kevin JosephCSO & EVP, Head of Research | SSale | −1.29K | $323.54 | −$417.7K | −5.9%20.6K after | 12 lots10b5-1 |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Poulton Jeffrey V.EVP, Chief Financial Officer | SSale | −2.21K | $327.65 | −$722.8K | −3.3%64.3K after | 10 lots |
| Mar 4, 2026 (view filing) | Mar 2-3 | 2 days | Garg PushkalEVP Chief R&D | SSale | −3.49K | $323.63 | −$1.13M | −13.0%23.4K after | 14 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 797 holdersThe largest institutional positions in Alnylam Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 15,023,962 | $4.52B | 0.20% | +444,796+3.1% | Added |
| Capital World Investors | 11,144,846 | $3.35B | 0.40% | +342,498+3.2% | Added |
| BlackRock, Inc. | 10,907,675 | $3.28B | 0.05% | +462,767+4.4% | Added |
| Capital Research Global Investors | 9,750,699 | $2.94B | 0.41% | +279,518+3.0% | Added |
| Vanguard Portfolio Management LLC | 6,538,390 | $1.97B | 0.09% | +47,110+0.7% | Added |
| Vanguard Capital Management LLC | 6,029,478 | $1.82B | 0.04% | +82,772+1.4% | Added |
| T. Rowe Price Investment Management, Inc. | 5,642,173 | $1.70B | 1.11% | +448,849+8.6% | Added |
| Invesco Ltd. | 3,754,318 | $1.13B | 0.09% | −320,802−7.9% | Reduced |
| State Street Corp | 3,555,689 | $1.07B | 0.03% | +232,991+7.0% | Added |
| Geode Capital Management, LLC | 2,635,840 | $791.3M | 0.04% | −24,545−0.9% | Reduced |
Holders of 5% or more of ALNY
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Alnylam Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 9.50%12.7M shares | −1.50 ppfrom 11.00% | Feb 8, 20219 filings | Nov 5, 2026 | SEC |
| Capital World Investors | 13G/A | 8.20%10.9M shares | – | Sep 9, 20224 filings | May 14, 2026 | SEC |
| Capital Research Global Investors | 13G/A | 7.10%9.47M shares | +1.70 ppfrom 5.40% | Feb 13, 20252 filings | May 14, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.35%7.10M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.03%6.73M shares | New | Oct 30, 20261 filing | Oct 30, 2026 | SEC |
Politician trades
All politician trades in ALNY4 members of Congress reported 10 trades in Alnylam Pharmaceuticals, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Sep 9, 2026 |  Cory A. Booker Senate · NJ | Sell (full) | $1K-$15K |
| Jun 22, 2025 |  Jefferson Shreve House · IN | Sell | $15K-$50K |
| Feb 15, 2024 |  Josh Gottheimer House · NJ | Buy | $1K-$15K |
| Feb 15, 2024 | Josh Gottheimer House · NJ | Sell | $1K-$15K |
| Jan 7, 2024 | Josh Gottheimer House · NJ | Sell | $1K-$15K |
Senate · NJ · Sep 9, 2026
Sell (full)$1K-$15K
House · IN · Jun 22, 2025
Sell$15K-$50K
House · NJ · Feb 15, 2024
Buy$1K-$15K
House · NJ · Feb 15, 2024
Sell$1K-$15K
House · NJ · Jan 7, 2024
Sell$1K-$15K